287 related articles for article (PubMed ID: 34403737)
1. Dopamine receptor D2 on CD4
Liu Z; Zhai XR; Du ZS; Xu FF; Huang Y; Wang XQ; Qiu YH; Peng YP
Brain Behav Immun; 2021 Nov; 98():110-121. PubMed ID: 34403737
[TBL] [Abstract][Full Text] [Related]
2. Dopamine receptor D3 expressed on CD4+ T cells favors neurodegeneration of dopaminergic neurons during Parkinson's disease.
González H; Contreras F; Prado C; Elgueta D; Franz D; Bernales S; Pacheco R
J Immunol; 2013 May; 190(10):5048-56. PubMed ID: 23589621
[TBL] [Abstract][Full Text] [Related]
3. Dopamine D2 receptor on CD4
Wang XQ; Cai HH; Deng QW; Chang YZ; Peng YP; Qiu YH
Arthritis Res Ther; 2023 May; 25(1):87. PubMed ID: 37237413
[TBL] [Abstract][Full Text] [Related]
4. Dopamine Receptor D3 Expression Is Altered in CD4
Elgueta D; Contreras F; Prado C; Montoya A; Ugalde V; Chovar O; Villagra R; Henríquez C; Abellanas MA; Aymerich MS; Franco R; Pacheco R
Front Immunol; 2019; 10():981. PubMed ID: 31118938
[TBL] [Abstract][Full Text] [Related]
5. IL-17A exacerbates neuroinflammation and neurodegeneration by activating microglia in rodent models of Parkinson's disease.
Liu Z; Qiu AW; Huang Y; Yang Y; Chen JN; Gu TT; Cao BB; Qiu YH; Peng YP
Brain Behav Immun; 2019 Oct; 81():630-645. PubMed ID: 31351185
[TBL] [Abstract][Full Text] [Related]
6. Drd2 biased agonist prevents neurodegeneration against NLRP3 inflammasome in Parkinson's disease model via a β-arrestin2-biased mechanism.
Zhu J; Sun T; Zhang J; Liu Y; Wang D; Zhu H; Yao H; Ding J; Hu G; Lu M
Brain Behav Immun; 2020 Nov; 90():259-271. PubMed ID: 32861720
[TBL] [Abstract][Full Text] [Related]
7. Intestinal Dopamine Receptor D2 is Required for Neuroprotection Against 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Dopaminergic Neurodegeneration.
Peng H; Yu S; Zhang Y; Yin Y; Zhou J
Neurosci Bull; 2022 Aug; 38(8):871-886. PubMed ID: 35399136
[TBL] [Abstract][Full Text] [Related]
8. RANTES-induced invasion of Th17 cells into substantia nigra potentiates dopaminergic cell loss in MPTP mouse model of Parkinson's disease.
Dutta D; Kundu M; Mondal S; Roy A; Ruehl S; Hall DA; Pahan K
Neurobiol Dis; 2019 Dec; 132():104575. PubMed ID: 31445159
[TBL] [Abstract][Full Text] [Related]
9. MPTP-driven NLRP3 inflammasome activation in microglia plays a central role in dopaminergic neurodegeneration.
Lee E; Hwang I; Park S; Hong S; Hwang B; Cho Y; Son J; Yu JW
Cell Death Differ; 2019 Jan; 26(2):213-228. PubMed ID: 29786072
[TBL] [Abstract][Full Text] [Related]
10. Programmed Death-1 Deficiency Aggravates Motor Dysfunction in MPTP Model of Parkinson's Disease by Inducing Microglial Activation and Neuroinflammation in Mice.
Cheng YY; Chen BY; Bian GL; Ding YX; Chen LW
Mol Neurobiol; 2022 Apr; 59(4):2642-2655. PubMed ID: 35142987
[TBL] [Abstract][Full Text] [Related]
11. Combining nitric oxide release with anti-inflammatory activity preserves nigrostriatal dopaminergic innervation and prevents motor impairment in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
L'Episcopo F; Tirolo C; Caniglia S; Testa N; Serra PA; Impagnatiello F; Morale MC; Marchetti B
J Neuroinflammation; 2010 Nov; 7():83. PubMed ID: 21092260
[TBL] [Abstract][Full Text] [Related]
12. Cannabidiol Alleviates the Damage to Dopaminergic Neurons in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Parkinson's Disease Mice Via Regulating Neuronal Apoptosis and Neuroinflammation.
Wang L; Wu X; Yang G; Hu N; Zhao Z; Zhao L; Li S
Neuroscience; 2022 Aug; 498():64-72. PubMed ID: 35792194
[TBL] [Abstract][Full Text] [Related]
13. Brain Selective Estrogen Treatment Protects Dopaminergic Neurons and Preserves Behavioral Function in MPTP-induced Mouse Model of Parkinson's Disease.
Thadathil N; Xiao J; Hori R; Alway SE; Khan MM
J Neuroimmune Pharmacol; 2021 Sep; 16(3):667-678. PubMed ID: 33221984
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of p38 pathway-dependent MPTP-induced dopaminergic neurodegeneration in estrogen receptor alpha knockout mice.
Hwang CJ; Choi DY; Jung YY; Lee YJ; Yun JS; Oh KW; Han SB; Oh S; Park MH; Hong JT
Horm Behav; 2016 Apr; 80():19-29. PubMed ID: 26836768
[TBL] [Abstract][Full Text] [Related]
15. A dysfunction of CD4+ T lymphocytes in peripheral immune system of Parkinson's disease model mice.
Huang Y; Liu Z; Wang XQ; Qiu YH; Peng YP
Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2014 Nov; 30(6):567-76. PubMed ID: 26016368
[TBL] [Abstract][Full Text] [Related]
16. Neuroprotective role of chloroquine via modulation of autophagy and neuroinflammation in MPTP-induced Parkinson's disease.
Kartik S; Pal R; Chaudhary MJ; Nath R; Kumar M; Binwal M; Bawankule DU
Inflammopharmacology; 2023 Apr; 31(2):927-941. PubMed ID: 36715843
[TBL] [Abstract][Full Text] [Related]
17. A role for glia maturation factor dependent activation of mast cells and microglia in MPTP induced dopamine loss and behavioural deficits in mice.
Selvakumar GP; Ahmed ME; Thangavel R; Kempuraj D; Dubova I; Raikwar SP; Zaheer S; Iyer SS; Zaheer A
Brain Behav Immun; 2020 Jul; 87():429-443. PubMed ID: 31982500
[TBL] [Abstract][Full Text] [Related]
18. TLR2 deficiency is beneficial at the late phase in MPTP-induced Parkinson' disease mice.
He Y; Zhao J; Dong H; Zhang X; Duan Y; Ma Y; Yu M; Fei J; Huang F
Life Sci; 2023 Nov; 333():122171. PubMed ID: 37827233
[TBL] [Abstract][Full Text] [Related]
19. PPARß/δ agonist alleviates NLRP3 inflammasome-mediated neuroinflammation in the MPTP mouse model of Parkinson's disease.
Chen L; Xue L; Zheng J; Tian X; Zhang Y; Tong Q
Behav Brain Res; 2019 Jan; 356():483-489. PubMed ID: 29885849
[TBL] [Abstract][Full Text] [Related]
20. Modeling of the Progressive Degradation of the Nigrostriatal Dopaminergic System in Mice to Study the Mechanisms of Neurodegeneration and Neuroplasticity in Parkinson's Disease.
Kolacheva A; Bannikova A; Pavlova E; Bogdanov V; Ugrumov M
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
